Content area

|
|

Nyt navn og nye behandlinger for primær biliær kolangitis

Forfatter(e)
Lars Bossen1, Henriette Ytting2, Peter Jepsen1, 3, Ole Hamberg2, Peter Ott1 & Henning Grønbæk1 1) Medicinsk Hepato-gastroenterologisk Afdeling V, Aarhus Universitetshospital 2) Hepatologisk Afdeling A, Rigshospitalet 3) Klinisk Epidemiologisk Afdeling, Aarhus Universitetshospital Ugeskr Læger 2018;180:V07170531
Reference: 
Ugeskr Læger 2018;180:V07170531
Blad nummer: 
Sidetal: 
2-5
New name and new treatments for primary biliary cholangitits
The name of chronic liver disease: primary biliary cirrhosis, has been changed to: primary biliary cholangitis, primarily because of the stigma associated with the word “cirrhosis”, as only a minority of the patients develop cirrhosis. In this review we present data on epidemiology and discuss the current treatments with focus on ursodeoxycholic acid and the newly described effects of the farnesoid receptor agonist obeticholic acid.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anders Heissel | 18/09
2 kommentarer
af Alice Kunkel | 17/09
7 kommentarer
af Jørn Rosborg | 17/09
1 Kommentar
af Peter Christian Gøtzsche | 17/09
1 Kommentar
af Jens Ole Mathiesen | 16/09
3 kommentarer
af Annette Randløv | 16/09
2 kommentarer
af Jens Ole Mathiesen | 15/09
4 kommentarer
af Jens Ole Mathiesen | 14/09
4 kommentarer
af Steffen Thirstrup | 11/09
4 kommentarer
af Jane Skjøth-Rasmussen | 11/09
8 kommentarer